Healthcare Costs of Metastatic Cutaneous Melanoma in the Era of Immunotherapeutic and Targeted Drugs

Immunotherapeutic and targeted drugs improved survival of patients with metastatic melanoma. There is, however, a lack of evidence regarding their healthcare costs in clinical practice. The aim of our study was to provide insight into real-world healthcare costs of patients with metastatic cutaneous...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancers (Basel)
Main Authors: Leeneman, Brenda, Uyl-de Groot, Carin A., Aarts, Maureen J. B., van Akkooi, Alexander C. J., van den Berkmortel, Franchette W. P. J., van den Eertwegh, Alfons J. M., de Groot, Jan Willem B., Herbschleb, Karin H., van der Hoeven, Jacobus J. M., Hospers, Geke A. P., Kapiteijn, Ellen, Piersma, Djura, van Rijn, Rozemarijn S., Suijkerbuijk, Karijn P. M., ten Tije, Albert J., van der Veldt, Astrid A. M., Vreugdenhil, Gerard, Wouters, Michel W. J. M., Haanen, John B. A. G., Franken, Margreet G.
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7225943/
https://ncbi.nlm.nih.gov/pubmed/32325748
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12041003
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados